Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

acute gouty arthritis(1,2). Patients had suffered from three or more gouty arthritis attacks in the previous 12 months and were either unresponsive or intolerant to common therapies like NSAIDs or colchicine, or these treatments were contraindicated. Patients were randomized to receive a single dose of ACZ885 150 milligrams (mg) via subcutaneous (s.c.) injection or TA 40 mg via intramuscular (i.m.) injection(1,2). In the case of a new attack, patients received a new dose of the same treatment they were randomized to at baseline.

Both studies had the same two primary endpoints: pain intensity at 72 hours post-dose; and time to the first new gouty arthritis attack(1,2). Pain in the affected joint was measured according to an internationally recognized pain scale, the Visual Analog Scale (VAS).

In one study, patients treated with ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 73.3 mm at baseline to 28.1 mm for ACZ885 vs. 74.8 mm at baseline to 39.5 mm for TA (p=0.0005)(1,16). Similarly, patients in the other study receiving ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 74.9 mm at baseline to 22.1 mm for ACZ885 vs. 73.6 mm at baseline to 31.9 mm for TA (p=0.0018)(17).

The number of patients with new attacks across both studies was also significantly reduced with ACZ885 compared to TA(2). In the first study, nearly twice as many patients experienced a new gouty arthritis attack in the TA group compared to ACZ885 (40 vs. 21 patients respectively [p=0.0061])(18). In addition, in the second study nearly three times as many patients in the TA group experienced a new attack compared to ACZ885 (42 vs. 15 patients respectively [p=0.0001])(18). In the previous year, patients in both studies suffered an average of at least six attacks (6.5 for ACZ885 and seven for TA in study one; and 6.5 and 5.9 respectively in study two)(16,17).

ACZ885 was generally wel
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... with no dose-limiting toxicities - - ... Halozyme to seek input from regulatory authorities in order to ... into pivotal clinical program ... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ...
... the identification of,the gene responsible for progeria, a ... of Spanish and French researchers (Carlos,Lopez-Otin and coll. ... and coll. -,Inserm/AP-HM, Marseille, France) have successfully demonstrated ... combining two existing,pharmacological molecules, should slow down the ...
Cached Medicine Technology:Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 2Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 3Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 4Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 5Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2
(Date:8/28/2015)... FL. (PRWEB) , ... August 28, 2015 , ... ... for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on ... that it should begin with the employer and employees getting together for meaningful ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s ... to Work in Healthcare by Modern Healthcare and will be honored at an ... its eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... a three-year accreditation for its adolescent residential, counseling, day treatment and intensive family ... it meets international standards for quality and its pursuit of excellence. As a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., ... resulting in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and ... the University of Illinois, and then went on to earn his title of Doctor ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... Two studies that offer new insights to help ... be presented by researchers from Cincinnati Childrens Hospital Medical ... Academic Society (PAS) in Honolulu, Hawaii. , One study, ... asthma dramatically overestimate their ability to control the condition, ...
... Misys plc (FTSE: MSY.L), the,global application software and services ... solutions have been selected by Masraf Al,Rayan to build ... Misys was chosen as the best partner for ... of its proven expertise in Islamic,finance and credibility in ...
... clipping a,pet parrots wings so that it can,t fly in ... pet birds then many people realize, and be,a violation of ... psychological problems as a,direct result from having their God given ... This lack of physical ability to fly and exercise ...
... Integrium, LLC(R), a,cardiovascular and metabolic focused clinical ... results, has officially launched,Integrium Clinical Excellence (ICE), a ... results on time and on,budget in all of ... is a,series of steps that provide a high ...
... 10 Percent Cuts from Taking,Effect July 1; Providers Say ... Calif., May 5 In an effort to,ensure that ... a coalition of health care providers today filed a ... 10 percent cut in,Medi-Cal and Denti-Cal payments from taking ...
... Natural Nutrition,Inc. (OTC Bulletin Board: NTNI) announced today that ... 2008 at 9 PM ET to discuss the upcoming ... iNutrition CEO Tim Connolly said, "iNutrition.com is all ... the very latest sports,lifestyle, and nutrition secrets for a ...
Cached Medicine News:Health News:Teens think they have asthma under control, but benefit from new approach to treatment 2Health News:Misys Facilitates Masraf Al Rayan's Expansion of Islamic Banking Operations 2Health News:Misys Facilitates Masraf Al Rayan's Expansion of Islamic Banking Operations 3Health News:How Clipping Pet Parrot's Wings May Violate Their Animal Rights 2Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 2Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 3Health News:Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials 4Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 2Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 3Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 4Health News:Health Care Providers Sue State of California Over Cuts in Medi-Cal Payments 5Health News:Natural Nutrition to Hold Conference Call on Launch of iNutrition.com 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: